Page last updated: 2024-12-11

eslicarbazepine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9881504
CHEMBL ID315985
CHEBI ID174358
SCHEMBL ID418933
MeSH IDM0572254

Synonyms (62)

Synonym
cgp-13751
bia-2-194
bia 2-194
eslicarbazepine
(s)-licarbazepine
CHEMBL315985
licarbazepine, (s)-
(5s)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
(s)-mhd
CHEBI:174358
104746-04-5
eslicarbazepine (usan/inn)
D09215
s-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide
(10s)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide
(10s)-10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5 carboxamide
(s)-(+)-10-hydroxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide
BMPDWHIDQYTSHX-AWEZNQCLSA-N
(s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide
(10s)-10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide
(10s)-10,11-dihydro-10-hydroxy-5h-dibenz(b,f)azepine-5-carboxamide
(10s)-10-hydroxy-10,11-dihydro-5h-dibenzo(b,f)azepin-5-carboxamide
s(+)-liscarbazepine
ec 810-248-9
eslicarbazepine [usan:inn:ban]
unii-s5vxa428r4
s5vxa428r4 ,
(10s)-10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepin-5-carboxamide
(s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz(b,f)azepine-5-carboxamide
5h-dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-hydroxy-, (10s)-
eslicarbazepine [who-dd]
eslicarbazepine [mi]
eslicarbazepine [usan]
eslicarbazepine [mart.]
eslicarbazepine [vandf]
eslicarbazepine [inn]
bia-2194
s-10-monohydroxy-dihydro-carbamazepin
gtpl7350
s-licarbazepine
SCHEMBL418933
AKOS016844866
(s)-10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide
5h-dibenz[b,f]azepine-5-carboxamide,10,11-dihydro-10-hydroxy-,(10s)-
J-001242
HY-114703
CS-0064132
DB14575
Q27077226
monohydroxy carbamazepine
(s)-licarbazepine; (10s)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide; s-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide
eslicarbazepine (bia 2-194)
MS-23581
(eslicarbazepine)
(s)-10-monohydroxy-10,11-dihydro carbamazepine
DTXSID901316900
EN300-18686811
(9s)-9-hydroxy-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide
eslicarbazepinum
eslicarbazepina
eslicarbazepine (mart.)
n03af04

Research Excerpts

Overview

Eslicarbazepine is a novel anti-epileptic agent indicated for the treatment of partial-onset seizures. It is chemically related to carbamazepine but with a more favorable safety profile.

ExcerptReferenceRelevance
"Eslicarbazepine is a novel anti-epileptic agent indicated for the treatment of partial-onset seizures. "( Intentional overdose of the novel anti-epileptic drug eslicarbazepine presenting with recurrent seizures and ventricular dysrhythmias.
Ovakim, DH; Powell, JD; Thompson, J, 2018
)
2.17
"Eslicarbazepine is a new anti-epileptic drug, chemically related to carbamazepine but with a more favorable safety profile."( Patch testing in a case of eslicarbazepine and carbamazepine induced cutaneous reaction.
Custódio, P; Finelli, E; Leiria-Pinto, P; Porovska, O; Prates, S, 2018
)
1.5
"Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) and an analogue to carbamazepine (CBZ) and oxcarbazepine (OXC). "( Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results.
Massot, A; Principe, A; Rocamora, R; Roquer, J; Vivanco, R, 2014
)
2.14
"Eslicarbazepine acetate is a recently approved antiepileptic drug that is rapidly metabolized to (S)-licarbazepine."( Oxcarbazepine and its active metabolite, (S)-licarbazepine, exacerbate seizures in a mouse model of genetic generalized epilepsy.
Kim, TH; Petrou, S; Reid, CA, 2015
)
1.14
"Eslicarbazepine acetate (ESL) is a new antiepileptic drug whose mechanism of action is blockade of the voltage-gated sodium channel (VGSC). "( Clinical utility of eslicarbazepine: current evidence.
Carelli, A; Cincotta, M; Giovannelli, F; Verrotti, A; Zaccara, G, 2015
)
2.18

Treatment

ExcerptReferenceRelevance
"Eslicarbazepine- and LCM-treated fast-inactivated channels recovered similarly to control conditions, whereas CBZ- and OXC-treated channels required longer pulses to recover."( Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide.
Bonifácio, MJ; Hebeisen, S; Loureiro, AI; Palma, N; Pires, N; Soares-da-Silva, P; Spanswick, D; Whyment, A, 2015
)
2.58

Pharmacokinetics

ExcerptReferenceRelevance
" This study evaluated the effect of multiple-dose ESL on the pharmacokinetic (PK) parameters of a single dose of rosuvastatin in healthy subjects."( Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Blum, D; Gidal, BE; Grinnell, T; Kharidia, J; Mintzer, S; Schutz, R; Schwab, M; Sunkaraneni, S, 2017
)
0.71

Bioavailability

ExcerptReferenceRelevance
" This study was performed to characterize the disposition of the two enantiomers of MHD after oral and intravenous administration and to estimate the bioavailability of MHD after a single oral dose administration of OXC compared to a single intravenous administration of MHD."( Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Czendlik, C; Flesch, G; Lloyd, P; Renard, D, 2011
)
0.37
"Rosuvastatin exposure was 36-39% lower with steady-state administration of ESL, potentially due to reduced oral bioavailability of rosuvastatin."( Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Blum, D; Gidal, BE; Grinnell, T; Kharidia, J; Mintzer, S; Schutz, R; Schwab, M; Sunkaraneni, S, 2017
)
0.71

Dosage Studied

ExcerptRelevanceReference
"Five groups of each of 12 female rats were orally dosed daily for 8 weeks with either carbamazepine (CBZ) (60 mg/kg), eslicarbazepine (ESL) (80 mg/kg), valproic acid (VPA) (300 mg/kg), levetiracetam (LEV) (50 mg/kg) or saline (control (CTL))."( Effects of carbamazepine, eslicarbazepine, valproic acid and levetiracetam on bone microarchitecture in rats.
Andersen, NB; Diemar, SS; Ding, M; Eiken, P; Ellegaard, M; Jørgensen, NR; Sejling, AS, 2020
)
1.07
" Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing."( Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dibenzooxazepineAn organic heterotricyclic compound consisting of two benzene rings fused to a seven-membered ring containing one oxygen and one nitrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID1220847Cmax in human treated with oxcarbazepine at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220850AUC (0 to 32/48 hrs) in human treated with oxcarbazepine at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220837Drug excretion in human urine assessed as total amount of drug eliminated treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220829Total plasma clearance in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as single dose by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220817AUC (0 to 72 hrs) in human treated with monohydroxy derivative of OXC at 200 mg, iv administered as single dose by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID195317Compound was tested for anticonvulsant activity against MES-induced seizures in rat1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1220825Total plasma clearance in human treated with monohydroxy derivative of OXC at 150 mg, iv administered as single dose by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220854Terminal half life in human urine treated with oxcarbazepine at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220846Tmax in human treated with oxcarbazepine at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220851Drug excretion in human urine assessed as total amount of drug eliminated treated with oxcarbazepine at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID190110Compound was tested intraperitoneally for anticonvulsant activity by rotarod test1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1220836AUC in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220815AUC (0 to 72 hrs) in human treated with monohydroxy derivative of OXC at 150 mg, iv administered as single dose by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220852Renal clearance in human treated with oxcarbazepine at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220835AUC (0 to 48 hrs) in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220838Total plasma clearance in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220842Terminal half life in human urine treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220827Total plasma clearance in human treated with monohydroxy derivative of OXC at 200 mg, iv administered as single dose by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220840Apparent terminal half life in human plasma treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220821Drug excretion in human urine assessed as total amount of drug eliminated treated with monohydroxy derivative of OXC at 150 mg, iv administered as single dose measured for 72 hrs post-dose by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID226935Protective index value of the compound, given by intraperitoneally (TD50/ED50)1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID176347Compound was tested intraperitoneally for anticonvulsant activity against MES-induced seizures in rat by MES test1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1220839Renal clearance in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220853Apparent terminal half life in human plasma treated with oxcarbazepine at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220841Volume of distribution at steady state in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID196513t max for anticonvulsant activity was tested in rats intraperitoneally1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1220819AUC (0 to 72 hrs) in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as single dose by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (2.44)18.2507
2000's0 (0.00)29.6817
2010's28 (68.29)24.3611
2020's12 (29.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.78 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index115.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (68.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (7.14%)5.53%
Reviews9 (21.43%)6.00%
Case Studies10 (23.81%)4.05%
Observational0 (0.00%)0.25%
Other20 (47.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]